Tvardi Therapeutics (TVRD) Amortizatization of Intangibles (2016 - 2026)
Tvardi Therapeutics (TVRD) posted Amortizatization of Intangibles of $35000.0 for Q1 2026, up 2.94% sequentially from $34000.0 in Q4 2025, and down 50.7% YoY from $71000.0 in Q1 2025.
Tvardi Therapeutics (TVRD) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Amortizatization of Intangibles for 11 years, with the latest figure at $35000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 50.7% year-over-year to $35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164000.0 (up 57.69% YoY) and the FY2025 annual result came in at $200000.0, down 63.17% from the prior year.
- Amortizatization of Intangibles climbed to $35000.0 in Q1 2026 per TVRD's latest filing, from $34000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $510000.0 in Q1 2024 and troughed at -$292000.0 in Q1 2022.
- A 5-year average of $60933.3 and a median of $35000.0 in 2026 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles jumped 442.55% in 2024, then slumped 86.08% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $234000.0 in 2022, then increased by 2.99% to $241000.0 in 2023, then slumped by 86.31% to $33000.0 in 2024, then gained by 3.03% to $34000.0 in 2025, then increased by 2.94% to $35000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $35000.0, $34000.0, and $25000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,000.00 |
| Mar 31, 2026 | 35,000.00 |
| Dec 31, 2025 | 34,000.00 |
| Dec 31, 2025 | 34,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 70,000.00 |
| Jun 30, 2025 | 70,000.00 |
| Mar 31, 2025 | 71,000.00 |
| Mar 31, 2025 | 71,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 510,000.00 |
| Mar 31, 2024 | 510,000.00 |
| Dec 31, 2023 | 241,000.00 |
| Dec 31, 2023 | 241,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Jun 30, 2023 | -38,000.00 |
| Jun 30, 2023 | -38,000.00 |